Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer

G. Chong, A. Bhatnagar, D. Cunningham, T. M. Cosgriff, P. G. Harper, W. Steward, J. Bridgewater, M. Moore, J. Cassidy, R. Coleman, F. Coxon, C. H. Redfern, J. J. Jones, R. Hawkins, Donald W Northfelt, S. Sreedharan, F. Valone, J. Carmichael

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune responses to CEA that may benefit colorectal cancer patients. Patients and methods: A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1(n = 422) or placebo (n = 208). Results: The addition of 3H1 to 5-FU and LV did not result in increased toxicity. Survival for the full intent-to-treat population was 14.7 months for the 3H1 arm and 15.2 months for the placebo arm (P = 0.80). Anti-CEA antibody responses were observed in 70% of patients treated with 3H1. Patients with a negative CEA response had a median survival of 8.3 months (95% CI 7.5 - 11.0) compared with patients with a strong response: median survival not reached (P <0.001). Conclusion: 3H1 is safe and effectively induces immune responses to CEA. Addition of 3H1 to 5-FU and LV was not shown to improve overall patient outcomes. However, improved survival in patients developing anti-CEA responses to 3H1 are provocative and should be studied in further clinical trials.

Original languageEnglish (US)
Pages (from-to)437-442
Number of pages6
JournalAnnals of Oncology
Volume17
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Leucovorin
Fluorouracil
Anti-Idiotypic Antibodies
Colorectal Neoplasms
Carcinoembryonic Antigen
Monoclonal Antibodies
Placebos
Survival
Antibody Formation
Clinical Trials

Keywords

  • Anti-idiotype
  • Antibody
  • Carcinoembryonic antigen
  • Colorectal
  • Response

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. / Chong, G.; Bhatnagar, A.; Cunningham, D.; Cosgriff, T. M.; Harper, P. G.; Steward, W.; Bridgewater, J.; Moore, M.; Cassidy, J.; Coleman, R.; Coxon, F.; Redfern, C. H.; Jones, J. J.; Hawkins, R.; Northfelt, Donald W; Sreedharan, S.; Valone, F.; Carmichael, J.

In: Annals of Oncology, Vol. 17, No. 3, 03.2006, p. 437-442.

Research output: Contribution to journalArticle

Chong, G, Bhatnagar, A, Cunningham, D, Cosgriff, TM, Harper, PG, Steward, W, Bridgewater, J, Moore, M, Cassidy, J, Coleman, R, Coxon, F, Redfern, CH, Jones, JJ, Hawkins, R, Northfelt, DW, Sreedharan, S, Valone, F & Carmichael, J 2006, 'Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer', Annals of Oncology, vol. 17, no. 3, pp. 437-442. https://doi.org/10.1093/annonc/mdj090
Chong, G. ; Bhatnagar, A. ; Cunningham, D. ; Cosgriff, T. M. ; Harper, P. G. ; Steward, W. ; Bridgewater, J. ; Moore, M. ; Cassidy, J. ; Coleman, R. ; Coxon, F. ; Redfern, C. H. ; Jones, J. J. ; Hawkins, R. ; Northfelt, Donald W ; Sreedharan, S. ; Valone, F. ; Carmichael, J. / Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. In: Annals of Oncology. 2006 ; Vol. 17, No. 3. pp. 437-442.
@article{0d88d804b595400a99fce1a48e941b51,
title = "Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer",
abstract = "Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune responses to CEA that may benefit colorectal cancer patients. Patients and methods: A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1(n = 422) or placebo (n = 208). Results: The addition of 3H1 to 5-FU and LV did not result in increased toxicity. Survival for the full intent-to-treat population was 14.7 months for the 3H1 arm and 15.2 months for the placebo arm (P = 0.80). Anti-CEA antibody responses were observed in 70{\%} of patients treated with 3H1. Patients with a negative CEA response had a median survival of 8.3 months (95{\%} CI 7.5 - 11.0) compared with patients with a strong response: median survival not reached (P <0.001). Conclusion: 3H1 is safe and effectively induces immune responses to CEA. Addition of 3H1 to 5-FU and LV was not shown to improve overall patient outcomes. However, improved survival in patients developing anti-CEA responses to 3H1 are provocative and should be studied in further clinical trials.",
keywords = "Anti-idiotype, Antibody, Carcinoembryonic antigen, Colorectal, Response",
author = "G. Chong and A. Bhatnagar and D. Cunningham and Cosgriff, {T. M.} and Harper, {P. G.} and W. Steward and J. Bridgewater and M. Moore and J. Cassidy and R. Coleman and F. Coxon and Redfern, {C. H.} and Jones, {J. J.} and R. Hawkins and Northfelt, {Donald W} and S. Sreedharan and F. Valone and J. Carmichael",
year = "2006",
month = "3",
doi = "10.1093/annonc/mdj090",
language = "English (US)",
volume = "17",
pages = "437--442",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer

AU - Chong, G.

AU - Bhatnagar, A.

AU - Cunningham, D.

AU - Cosgriff, T. M.

AU - Harper, P. G.

AU - Steward, W.

AU - Bridgewater, J.

AU - Moore, M.

AU - Cassidy, J.

AU - Coleman, R.

AU - Coxon, F.

AU - Redfern, C. H.

AU - Jones, J. J.

AU - Hawkins, R.

AU - Northfelt, Donald W

AU - Sreedharan, S.

AU - Valone, F.

AU - Carmichael, J.

PY - 2006/3

Y1 - 2006/3

N2 - Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune responses to CEA that may benefit colorectal cancer patients. Patients and methods: A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1(n = 422) or placebo (n = 208). Results: The addition of 3H1 to 5-FU and LV did not result in increased toxicity. Survival for the full intent-to-treat population was 14.7 months for the 3H1 arm and 15.2 months for the placebo arm (P = 0.80). Anti-CEA antibody responses were observed in 70% of patients treated with 3H1. Patients with a negative CEA response had a median survival of 8.3 months (95% CI 7.5 - 11.0) compared with patients with a strong response: median survival not reached (P <0.001). Conclusion: 3H1 is safe and effectively induces immune responses to CEA. Addition of 3H1 to 5-FU and LV was not shown to improve overall patient outcomes. However, improved survival in patients developing anti-CEA responses to 3H1 are provocative and should be studied in further clinical trials.

AB - Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune responses to CEA that may benefit colorectal cancer patients. Patients and methods: A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1(n = 422) or placebo (n = 208). Results: The addition of 3H1 to 5-FU and LV did not result in increased toxicity. Survival for the full intent-to-treat population was 14.7 months for the 3H1 arm and 15.2 months for the placebo arm (P = 0.80). Anti-CEA antibody responses were observed in 70% of patients treated with 3H1. Patients with a negative CEA response had a median survival of 8.3 months (95% CI 7.5 - 11.0) compared with patients with a strong response: median survival not reached (P <0.001). Conclusion: 3H1 is safe and effectively induces immune responses to CEA. Addition of 3H1 to 5-FU and LV was not shown to improve overall patient outcomes. However, improved survival in patients developing anti-CEA responses to 3H1 are provocative and should be studied in further clinical trials.

KW - Anti-idiotype

KW - Antibody

KW - Carcinoembryonic antigen

KW - Colorectal

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=33644669737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644669737&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdj090

DO - 10.1093/annonc/mdj090

M3 - Article

C2 - 16311275

AN - SCOPUS:33644669737

VL - 17

SP - 437

EP - 442

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -